Search

Subject Angiosarcoma -- Regorafenib -- Sarcoma -- TKI -- Phase 2

1. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. (September 2021)

Authors:
Agulnik, Mark; Schulte, Brian; Robinson, Steven; Hirbe, Angela C.; Kozak, Kevin; Chawla, Sant P.; Attia, Steven; Rademaker, Alfred; Zhang, Hui; Abbinanti, Susan; Cehic, Rasima; Monga, Varun; Milhem, Mohammed; Okuno, Scott; Van Tine, Brian A.
Journal:
European journal of cancer
Issue:
Volume 154(2021)
Page Start:
201
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • Angiosarcoma -- Regorafenib -- Sarcoma -- TKI -- Phase 2 1